Halozyme Therapeutics (MIL:1HALO) Cyclically Adjusted FCF per Share: €1.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1HALO Halozyme Therapeutics Inc MIL:1HALO
65 GF Score
Price €93.10
GF Value €61.97
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Halozyme Therapeutics Cyclically Adjusted FCF per Share?

Halozyme Therapeutics MIL:1HALO 65 Cyclically Adjusted FCF per Share is €1.81 as of Jun. 2026. GuruFocus rates MIL:1HALO with a GF Score™ of 65/100 and a GF Value™ of €61.97 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Halozyme Therapeutics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €1.687. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €1.81 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Halozyme Therapeutics's average Cyclically Adjusted FCF Growth Rate was 43.90% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 83.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Halozyme Therapeutics was 83.10% per year. The lowest was -12.90% per year. And the median was 2.90% per year.

As of today (2026-09-15), Halozyme Therapeutics's current stock price is €93.10. Halozyme Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €1.81. Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is 51.52.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 41.53. And the median was 68.75.


Halozyme Therapeutics  (MIL:1HALO) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=93.10/1.807
=51.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Halozyme Therapeutics was 1610.00. The lowest was 41.53. And the median was 68.75.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Halozyme Therapeutics Cyclically Adjusted FCF per Share Related Terms


Halozyme Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Halozyme Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics Cyclically Adjusted FCF per Share Chart

Halozyme Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.22 0.53 0.92 1.44

Halozyme Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.13 1.27 1.44 1.61 1.81

MIL:1HALO vs ARWR, CORT, MDGL: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halozyme Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


MIL:1HALO
65GF Score
Halozyme Therapeutics Inc MIL:1HALO
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Halozyme Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Halozyme Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.687/333.9520*333.9520
=1.687

Current CPI (Jun. 2026) = 333.9520.

Halozyme Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.066 241.428 -0.091
201612 -0.126 241.432 -0.174
201703 -0.165 243.801 -0.226
201706 -0.112 244.955 -0.153
201709 0.135 246.819 0.183
201712 0.889 246.524 1.204
201803 -0.131 249.554 -0.175
201806 -0.117 251.989 -0.155
201809 -0.121 252.439 -0.160
201812 0.038 251.233 0.051
201903 -0.032 254.202 -0.042
201906 -0.160 256.143 -0.209
201909 -0.191 256.759 -0.248
201912 -0.176 256.974 -0.229
202003 -0.033 258.115 -0.043
202006 0.018 257.797 0.023
202009 0.036 260.280 0.046
202012 0.284 260.474 0.364
202103 0.324 264.877 0.408
202106 0.204 271.696 0.251
202109 0.713 274.310 0.868
202112 0.539 278.802 0.646
202203 0.298 287.504 0.346
202206 0.275 296.311 0.310
202209 0.523 296.808 0.588
202212 0.554 296.797 0.623
202303 0.511 301.836 0.565
202306 0.464 305.109 0.508
202309 0.888 307.789 0.963
202312 0.731 306.746 0.796
202403 0.900 312.332 0.962
202406 0.390 314.175 0.415
202409 0.771 315.301 0.817
202412 1.337 315.605 1.415
202503 1.150 319.799 1.201
202506 0.614 322.561 0.636
202509 1.174 324.800 1.207
202512 1.601 324.054 1.650
202603 1.227 330.213 1.241
202606 1.687 333.952 1.687

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €1.81 mean?
Halozyme Therapeutics (MIL:1HALO) has a Cyclically Adjusted FCF per Share of €1.81 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors.
Is Halozyme Therapeutics' Cyclically Adjusted FCF per Share too high?
Halozyme Therapeutics' current Cyclically Adjusted FCF per Share is €1.81. Overall, Halozyme Therapeutics has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Halozyme Therapeutics' Cyclically Adjusted FCF per Share compare to ARWR and CORT?
Halozyme Therapeutics' Cyclically Adjusted FCF per Share of €1.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Halozyme Therapeutics and its competitors. Halozyme Therapeutics's current Cyclically Adjusted FCF per Share is €1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halozyme Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Halozyme Therapeutics (MIL:1HALO) is currently considered Significantly Overvalued. The stock's GF Value™ is €61.97, compared to a current price of €93.10 — trading 50.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €1.81. Halozyme Therapeutics' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Halozyme Therapeutics (MIL:1HALO), the current Cyclically Adjusted FCF per Share is €1.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Halozyme Therapeutics (MIL:1HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be overvalued. The current stock price of €93.10 is trading 50.2% above its estimated GF Value™ of €61.97. GuruFocus considers Halozyme Therapeutics to be Significantly Overvalued.

Key valuation signals for MIL:1HALO:

  • Cyclically Adjusted FCF per Share: €1.81
  • GF Value™: €61.97 vs. price of €93.10 (50.2% above fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the MIL:1HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
65GF Score

Get the complete analysis for MIL:1HALO

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€93.10
Price
€61.97
GF Value